dewpoint logo


June 25, 2024

Dewpoint Therapeutics Strengthens Collaboration with Novo Nordisk to Accelerate Drug Discovery

BOSTON, Massachusetts, June 25, 2024 – Just over a year after the start of its collaboration, Dewpoint Therapeutics and Novo Nordisk have decided to expand their research and development partnership. The new agreement utilizes Dewpoint’s high-throughput screening platform combined with genome-wide CRISPR screens.   

Key goals of the expanded partnership:

  • Leverage Dewpoint’s state-of-the-art platform and expertise in high content image-based phenotypic high throughput screening (HTS) with Novo Nordisk’s Target Discovery Engine.
  • Create translatable tools and procedures that, in the future, will be applied to expedite drug discovery efforts.

This new collaboration is a testament to the shared commitment of both companies to advance drug discovery and improve patient outcomes.

Media Contact

Investor Contact

Michael Fenn, PH.D.
Head of External Innovation
Dewpoint Therapeutics
dewpoint logo
Dewpoint Therapeutics
451 D Street, Suite 104
Boston, MA 02210
© 2019-2024 - Dewpoint Therapeutics

Design: SALIENCE Communication / Publiepress
Scientific animation: Visual Science